ALK Abello publishes 16-month report

ALK Abello has published a 16-month report and financial statements for the period ended December 2007. The company generated revenues of 15.75 million pounds during the period and an operating profit of 363,302 pounds. ALK Abello was the first company to launch sublingual immunotherapy – vaccines administered under the tongue – in the 1990s.